- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Alkem Labs unveils Ibuprofen, Famotidine Tablets in US
Mumbai: Alkem Laboratories Ltd. today announced the launch of Ibuprofen and Famotidine Tablets (800 mg/26.6 mg) in the United States, following an approval from the United States Food and Drug Administration (USFDA). Ibuprofen and Famotidine Tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC's Duexis Tablets, 800 mg/26.6 mg."This is the first generic...
Mumbai: Alkem Laboratories Ltd. today announced the launch of Ibuprofen and Famotidine Tablets (800 mg/26.6 mg) in the United States, following an approval from the United States Food and Drug Administration (USFDA).
Ibuprofen and Famotidine Tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC's Duexis Tablets, 800 mg/26.6 mg.
"This is the first generic approval of Duexis Tablets, 800 mg/26.6 mg by the US FDA. The launch is a subject of ongoing litigation," Alkem Labs said in a release.
Read also: Alkem labs successfully completes USFDA inspection for Taloja Bioequivalence Center
Read also: Alkem Labs launches epilepsy drug Perampil in India
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751